What are the next steps for a patient with dermatomyositis showing evidence of ongoing inflammation despite treatment with mycophenolate, Actemra (tocilizumab), high-dose Intravenous Immunoglobulin (IVIG), prednisone, Plaquenil (hydroxychloroquine), and Rituximab (rituximab)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 25, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a patient with dermatomyositis showing evidence of ongoing inflammation despite treatment with mycophenolate, actemra, high-dose IVIG, prednisone, plaquenil, and rituximab, the next steps should involve considering intensification of immunosuppressive therapy, potentially including intravenous cyclophosphamide, as recommended by experts in the field 1.

Given the patient's refractory disease, it is crucial to reassess the current treatment regimen and consider alternative or additional therapies that may help achieve better disease control. The expert consensus recommends that in patients with severe disease, such as major organ involvement or extensive ulcerative skin disease, the addition of intravenous cyclophosphamide should be considered 1.

Some key points to consider in managing this patient include:

  • Evaluating the patient's response to current therapies and adjusting the treatment plan as necessary, with the goal of minimizing disease activity and preventing long-term damage.
  • Considering the use of intravenous cyclophosphamide as an adjunctive therapy for severe or refractory disease, as recommended by experts in the field 1.
  • Assessing the patient's overall health and adjusting the treatment plan to minimize potential side effects and optimize quality of life.
  • Regularly monitoring the patient's disease activity and adjusting the treatment plan as necessary to achieve optimal disease control.

It is also essential to note that the patient's ongoing skin disease may reflect ongoing systemic disease, and therefore, increasing systemic immunosuppression may be necessary to achieve better disease control 1. Additionally, considering the patient's current treatment regimen, which includes rituximab, it is essential to be aware that rituximab can take up to 26 weeks to work, and therefore, it may be necessary to continue this therapy for an adequate duration before assessing its efficacy 1.

In terms of specific treatment options, the expert consensus recommends that intravenous cyclophosphamide can be considered for patients with severe disease, and that anti-TNF therapies, such as infliximab or adalimumab, can also be considered in refractory cases 1. However, it is crucial to carefully weigh the potential benefits and risks of these therapies and to closely monitor the patient's response to treatment.

Ultimately, the goal of treatment should be to achieve optimal disease control, minimize potential side effects, and optimize the patient's quality of life. By considering the expert consensus recommendations and carefully evaluating the patient's individual needs and response to treatment, it is possible to develop an effective treatment plan that addresses the patient's ongoing inflammation and improves their overall health outcomes.

From the Research

Ongoing Inflammation in Dermatomyositis

  • The patient is experiencing ongoing inflammation despite treatment with mycophenolate, actemra, high dose ivig, prednisone, plaquenil, and rituximab for dermatomyositis.
  • A study published in 2009 2 found that intravenous immunoglobulin (IVIg) as an add-on treatment with mycophenolate mofetil (MMF) was effective in severe and refractory myositis, and was a safe and steroid-sparing agent.

Next Steps

  • Considering the patient's multidrug-resistant disease, a possible next step could be to try intravenous cyclophosphamide (IVCY) as a remission induction therapy, followed by maintenance therapy with MMF, as seen in a case study of IgA vasculitis 3.
  • Another option could be to compare the efficacy and safety of glucocorticoids combined with cyclophosphamide (CYC) or mycophenolate mofetil (MMF) in treating the patient's disease, as studied in IgG4-related disease patients 4.

Resolution of Inflammation

  • The resolution of inflammation is an actively regulated process, and understanding the endogenous processes that govern normal resolution of acute inflammation is critical for determining why chronic unresolved inflammation perpetuates 5, 6.
  • Resolvins have emerged as a genus of evolutionarily conserved proresolving mediators that act on specific cellular receptors to regulate leukocyte trafficking and blunt production of inflammatory mediators, while also promoting clearance of dead cells and tissue repair 6.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the role of early intravenous immunoglobulin (IVIG) in the treatment of myositis-associated interstitial lung disease (ILD)?
Is IVIG (Intravenous Immunoglobulin) therapy at a dose of 1 gram/kg IV per day for two days every 4 weeks medically necessary and considered standard of care for a patient with dermatomyositis who is not responding adequately to prednisone, tacrolimus, and mycophenolate mofetil?
What is the street name for Lisdexamfetamine (Vyvanse) used to treat Binge Eating Disorder (BED)?
What are the differential diagnoses for respiratory alkalosis?
What CHADS-VASc (Cardiac failure, Hypertension, Age ≥ 75 years, Diabetes, Stroke or transient ischemic attack) score is anticoagulation recommended?
What is the significance of a 55-year-old male with prediabetes having impaired renal function, as indicated by elevated creatinine levels and microalbumin/creatinine ratio?
What is the significance of a serum iron level of 103 micrograms per deciliter (mcg/dL), Total Iron-Binding Capacity (TIBC) of 475 mcg/dL, and iron saturation of 22%?
What are the sounds of carotid arteries in a patient with Congestive Heart Failure (CHF)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question